8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Mar 30, 2026·SEC
Viridian Therapeutics, Inc.(VRDN)Earnings, Financials & Key Ratios
VRDN•NASDAQ
$16.97
$1.44B mkt cap·Price updated May 7, 2026
AboutViridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$71M+23359.9%
- EBITDA-$363M-21.9%
- Net Income-$343M-26.9%
- EPS (Diluted)-3.32+16.6%
- Gross Margin100%
- EBITDA Margin-512.27%+99.5%
- Operating Margin-512.91%+99.5%
- Net Margin-483.56%+99.5%
- ROE-49.16%-1.4%
- ROIC-47.25%-0.4%
- Debt/Equity0.07+123.5%
- Interest Coverage-68.24+22.1%
VRDN Key Insights
Viridian Therapeutics, Inc. (VRDN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 132.2%
✗Weaknesses
- ✗Profits declining 25.3% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 6 (bottom 6%)
- ✗Shares diluted 24.9% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
VRDN Price & Volume
Viridian Therapeutics, Inc. (VRDN) stock price & volume — 10-year historical chart
Loading chart...
VRDN Growth Metrics
Viridian Therapeutics, Inc. (VRDN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years39.5%
5 Years132.18%
3 Years241.95%
TTM23382.78%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-16.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM9.61%
Return on Capital
10 Years-93.61%
5 Years-50.97%
3 Years-52.71%
Last Year-47.71%
VRDN Recent Earnings
Viridian Therapeutics, Inc. (VRDN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 6/12 qtrs (55%)
Q2 2026Latest
May 5, 2026EPS
$0.90
Est $1.06
+15.1%
Revenue
$141,000
Est $36,083
+290.8%
Q1 2026
Feb 26, 2026EPS
$1.08
Est $0.90
-20.0%
Revenue
$132,000
Est $18M
-99.3%
Q4 2025
Nov 5, 2025EPS
$0.34
Est $0.82
+58.5%
Revenue
$71M
Est $16M
+348.1%
Q3 2025
Aug 6, 2025EPS
$1.00
Est $1.00
+0.0%
Revenue
$75,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.90vs $1.06+15.1% | $141,000vs $36,083+290.8% |
| Q1 2026 | Feb 26, 2026 | $1.08vs $0.90-20.0% | $132,000vs $18M-99.3% |
| Q4 2025 | Nov 5, 2025 | $0.34vs $0.82+58.5% | $71Mvs $16M+348.1% |
| Q3 2025 | Aug 6, 2025 | $1.00vs $1.00+0.0% | $75,000 |
Based on last 12 quarters of dataView full earnings history →
VRDN Peer Comparison
Viridian Therapeutics, Inc. (VRDN) competitors in Ophthalmology Therapies and Delivery — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.53B | 27.22 | -9.97 | -47.07% | 0.00 | |||
 RDVT | 692.78M | 49.09 | 53.95 | 20.03% | 14.99% | 13.98% | 0.03 | |
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 9.63B | 333.28 | -24.72 | -100% | -43.02% | 0.00 | ||
 AMGN | 177.59B | 329.06 | 23.12 | 9.92% | 20.95% | 89.41% | 6.31 | |
 REGN | 73.68B | 709.10 | 17.10 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ALNY | 39.48B | 295.91 | 127 | 65.19% | 13.46% | 98.29% | 1.62 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare VRDN vs Peers
Viridian Therapeutics, Inc. (VRDN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VRDN Income Statement
Viridian Therapeutics, Inc. (VRDN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4M | 8.39M | 4.46M | 1.05M | 2.96M | 1.77M | 314K | 302K | 70.85M | 70.92M |
| Revenue Growth % | 19.96% | 109.49% | -46.8% | -76.46% | 182.19% | -40.2% | -82.28% | -3.82% | 23359.93% | 23382.78% |
| Cost of Goods Sold | 19.62M | 30.42M | 0 | 28.3M | 0 | 0 | 0 | 0 | 0 | 441K |
| COGS % of Revenue | 490.21% | 362.76% | - | 2695.62% | - | - | - | - | - | - |
| Gross Profit | -15.62M▲ 0% | -22.04M▼ 41.1% | 4.46M▲ 120.2% | -27.25M▼ 710.9% | 2.96M▲ 110.9% | 1.77M▼ 40.2% | 314K▼ 82.3% | 302K▼ 3.8% | 70.85M▲ 23359.9% | 70.48M▲ 0% |
| Gross Margin % | -390.21% | -262.76% | 100% | -2595.62% | 100% | 100% | 100% | 100% | 100% | 99.38% |
| Gross Profit Growth % | -2079.72% | -41.07% | 120.25% | -710.94% | 110.87% | -40.2% | -82.28% | -3.82% | 23359.93% | - |
| Operating Expenses | 30.54M | 41.47M | 46.44M | 83.13M | 82.69M | 136.08M | 254.76M | 299.34M | 434.24M | 456.3M |
| OpEx % of Revenue | 762.8% | 494.51% | 1041.02% | 7916.76% | 2790.79% | 7679.23% | 81135.03% | 99118.21% | 612.91% | - |
| Selling, General & Admin | 10.91M | 11.05M | 11.65M | 13.27M | 25.8M | 35.18M | 95M | 61.08M | 95.31M | 116.89M |
| SG&A % of Revenue | 272.6% | 131.76% | 261.06% | 1263.33% | 870.91% | 1985.44% | 30254.46% | 20226.16% | 134.53% | - |
| Research & Development | 19.62M | 30.42M | 34.79M | 28.3M | 56.89M | 100.89M | 159.76M | 238.25M | 338.93M | 339.73M |
| R&D % of Revenue | 490.21% | 362.76% | 779.96% | 2695.62% | 1919.88% | 5693.79% | 50880.57% | 78892.05% | 478.38% | - |
| Other Operating Expenses | 0 | 0 | 0 | 41.56M | 0 | 0 | 0 | 0 | 0 | -320K |
| Operating Income | -26.53M▲ 0% | -33.08M▼ 24.7% | -41.98M▼ 26.9% | -110.38M▼ 162.9% | -79.73M▲ 27.8% | -134.3M▼ 68.5% | -254.45M▼ 89.5% | -299.04M▼ 17.5% | -363.39M▼ 21.5% | -385.7M▲ 0% |
| Operating Margin % | -662.8% | -394.51% | -941.02% | -10512.38% | -2690.79% | -7579.23% | -81035.03% | -99018.21% | -512.91% | -543.86% |
| Operating Income Growth % | -112.12% | -24.69% | -26.89% | -162.94% | 27.77% | -68.45% | -89.46% | -17.52% | -21.52% | - |
| EBITDA | -26.22M | -32.8M | -41.69M | -110.14M | -79.61M | -134.05M | -253.93M | -297.8M | -362.94M | -385.69M |
| EBITDA Margin % | -655.11% | -391.16% | -934.57% | -10489.62% | -2686.74% | -7564.84% | -80868.79% | -98607.62% | -512.27% | -543.86% |
| EBITDA Growth % | -115.53% | -25.09% | -27.1% | -164.18% | 27.72% | -68.39% | -89.43% | -17.28% | -21.87% | -14.62% |
| D&A (Non-Cash Add-back) | 308K | 281K | 288K | 239K | 120K | 255K | 522K | 1.24M | 460K | 4K |
| EBIT | -26.13M | -31.83M | -41.04M | -40.52M | -79.41M | -129.39M | -235.89M | -266.9M | -337.65M | -364.18M |
| Net Interest Income | 20K | 381K | 106K | -335K | 315K | 4.43M | 16.72M | 29.09M | 22.45M | 16.59M |
| Interest Income | 403K | 1.25M | 941K | 173K | 318K | 4.92M | 18.56M | 32.13M | 27.4M | 27.73M |
| Interest Expense | 383K | 873K | 835K | 508K | 3K | 486K | 1.85M | 3.05M | 4.95M | 11.14M |
| Other Income/Expense | 20K | 381K | 106K | -335K | 315K | 4.43M | 16.72M | 29.09M | 20.79M | 25.11M |
| Pretax Income | -26.51M▲ 0% | -32.7M▼ 23.4% | -41.87M▼ 28.0% | -110.72M▼ 164.4% | -79.41M▲ 28.3% | -129.87M▼ 63.5% | -237.73M▼ 83.0% | -269.95M▼ 13.6% | -342.6M▼ 26.9% | -360.59M▲ 0% |
| Pretax Margin % | -662.3% | -389.97% | -938.65% | -10544.29% | -2680.16% | -7329.23% | -75711.46% | -89387.09% | -483.56% | -508.46% |
| Income Tax | 95K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.36% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -26.51M▲ 0% | -32.7M▼ 23.4% | -41.87M▼ 28.0% | -110.72M▼ 164.4% | -79.41M▲ 28.3% | -129.87M▼ 63.5% | -237.73M▼ 83.0% | -269.95M▼ 13.6% | -342.6M▼ 26.9% | -360.59M▲ 0% |
| Net Margin % | -662.3% | -389.97% | -938.65% | -10544.29% | -2680.16% | -7329.23% | -75711.46% | -89387.09% | -483.56% | -508.46% |
| Net Income Growth % | -109.18% | -23.35% | -28.04% | -164.41% | 28.27% | -63.54% | -83.05% | -13.55% | -26.91% | -16.95% |
| Net Income (Continuing) | -26.51M | -32.7M | -41.87M | -110.72M | -79.41M | -129.87M | -237.73M | -269.95M | -342.6M | -360.59M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -20.66▲ 0% | -16.57▲ 19.8% | -20.31▼ 22.6% | -31.20▼ 53.6% | -6.66▲ 78.7% | -3.91▲ 41.3% | -5.31▼ 35.8% | -3.98▲ 25.0% | -3.32▲ 16.6% | -3.53▲ 0% |
| EPS Growth % | -17.59% | 19.8% | -22.57% | -53.62% | 78.65% | 41.29% | -35.81% | 25.05% | 16.58% | 9.61% |
| EPS (Basic) | -20.66 | -16.57 | -20.31 | -31.20 | -6.66 | -3.91 | -5.31 | -3.98 | -3.32 | - |
| Diluted Shares Outstanding | 1.28M | 1.97M | 2.09M | 3.56M | 11.92M | 32.09M | 44.76M | 67.89M | 84.8M | 102.21M |
| Basic Shares Outstanding | 1.28M | 1.97M | 2.09M | 3.56M | 11.92M | 32.09M | 44.76M | 67.89M | 84.8M | 102.21M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VRDN Balance Sheet
Viridian Therapeutics, Inc. (VRDN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 51.87M | 65.37M | 29.74M | 129.61M | 200.16M | 424.55M | 486.48M | 738.46M | 894.23M | 784.74M |
| Cash & Short-Term Investments | 47.44M | 62.48M | 26.84M | 127.64M | 196.97M | 424.55M | 477.37M | 717.58M | 874.65M | 762.18M |
| Cash Only | 47.44M | 32.61M | 24.85M | 45.9M | 42.3M | 155.58M | 102.83M | 99.59M | 212.38M | 176.35M |
| Short-Term Investments | 0 | 29.88M | 2M | 81.74M | 154.67M | 268.97M | 374.54M | 617.99M | 662.27M | 585.84M |
| Accounts Receivable | 1.46M | 24K | 108K | 0 | 451K | 102K | 102K | 0 | 0 | 0 |
| Days Sales Outstanding | 132.76 | 1.04 | 8.84 | - | 55.56 | 21.01 | 118.57 | - | - | 90.07 |
| Inventory | 0 | 0 | 0 | 0 | 0 | -6.62M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 2.97M | 2.87M | -108K | 0 | 0 | 6.52M | 9.01M | 20.88M | 19.58M | 22.56M |
| Total Non-Current Assets | 613K | 777K | 523K | 1.64M | 3.55M | 10.54M | 3.95M | 3.94M | 5.18M | 4.27M |
| Property, Plant & Equipment | 563K | 727K | 523K | 787K | 2.06M | 2.94M | 3.34M | 3.44M | 3.65M | 3.38M |
| Fixed Asset Turnover | 7.11x | 11.54x | 8.53x | 1.33x | 1.44x | 0.60x | 0.09x | 0.09x | 19.42x | 20.54x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 50K | 50K | 0 | 857K | 1.49M | 7.61M | 604K | 501K | 1.54M | 4.45M |
| Total Assets | 52.48M▲ 0% | 66.15M▲ 26.0% | 30.26M▼ 54.3% | 131.25M▲ 333.7% | 203.71M▲ 55.2% | 435.09M▲ 113.6% | 490.42M▲ 12.7% | 742.4M▲ 51.4% | 899.42M▲ 21.1% | 789.02M▲ 0% |
| Asset Turnover | 0.08x | 0.13x | 0.15x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.08x | 0.10x |
| Asset Growth % | 1132.24% | 26.04% | -54.25% | 333.73% | 55.2% | 113.58% | 12.72% | 51.38% | 21.15% | 14.72% |
| Total Current Liabilities | 3.9M | 6.73M | 10.18M | 10.67M | 13.64M | 33.35M | 26.64M | 47.87M | 70.7M | 51.8M |
| Accounts Payable | 906K | 571K | 1.1M | 670K | 2.33M | 14.23M | 2.24M | 2.14M | 8.68M | 13.31M |
| Days Payables Outstanding | 16.85 | 6.85 | - | 8.64 | - | - | - | - | - | 8.4K |
| Short-Term Debt | 0 | 2.29M | 3.98M | 0 | 0 | 0 | 0 | 0 | 753K | 738K |
| Deferred Revenue (Current) | 0 | 3.79M | 0 | 301K | 289K | 288K | 288K | 288K | 0 | 934K |
| Other Current Liabilities | 353K | 239K | 674K | 7.29M | 3.75M | 4.87M | 12.75M | 10.74M | 61.26M | 29.12M |
| Current Ratio | 13.31x | 9.71x | 2.92x | 12.14x | 14.68x | 12.73x | 18.26x | 15.43x | 12.65x | 12.65x |
| Quick Ratio | 13.31x | 9.71x | 2.92x | 12.14x | 14.68x | 12.93x | 18.26x | 15.43x | 12.65x | 12.65x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -8.31K |
| Total Non-Current Liabilities | 10.07M | 8.07M | 4.33M | 544K | 2.36M | 6.68M | 21.77M | 22.89M | 106.56M | 101.2M |
| Long-Term Debt | 9.92M | 8M | 4.33M | 0 | 0 | 4.64M | 20.2M | 20.58M | 49.94M | 50.44M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.2M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 152K | 66K | 0 | 544K | 1.21M | 1.17M | 989K | 2.02M | 56.62M | 109.84M |
| Total Liabilities | 13.97M | 14.8M | 14.51M | 11.22M | 15.99M | 40.03M | 48.4M | 70.76M | 177.25M | 153.01M |
| Total Debt | 9.92M | 10.3M | 8.3M | 455K | 520K | 5.26M | 21.05M | 21.09M | 50.69M | 51.17M |
| Net Debt | -37.52M | -22.31M | -16.54M | -45.44M | -41.78M | -150.32M | -81.78M | -78.5M | -161.69M | -125.17M |
| Debt / Equity | 0.26x | 0.20x | 0.53x | 0.00x | 0.00x | 0.01x | 0.05x | 0.03x | 0.07x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.13x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.32x |
| Interest Coverage | -68.22x | -36.46x | -49.15x | -79.76x | -26470.00x | -266.23x | -127.71x | -87.62x | -68.24x | -32.68x |
| Total Equity | 38.51M▲ 0% | 51.34M▲ 33.3% | 15.75M▼ 69.3% | 120.04M▲ 661.9% | 187.72M▲ 56.4% | 395.06M▲ 110.5% | 442.02M▲ 11.9% | 671.64M▲ 51.9% | 722.17M▲ 7.5% | 636.01M▲ 0% |
| Equity Growth % | 11912.88% | 33.33% | -69.32% | 661.95% | 56.38% | 110.46% | 11.89% | 51.95% | 7.52% | -18.85% |
| Book Value per Share | 30.02 | 26.02 | 7.54 | 33.75 | 15.75 | 12.31 | 9.88 | 9.89 | 8.52 | 6.22 |
| Total Shareholders' Equity | 38.51M | 51.34M | 15.75M | 120.04M | 187.72M | 395.06M | 442.02M | 671.64M | 722.17M | 636.01M |
| Common Stock | 226K | 308K | 23K | 42K | 239K | 414K | 540K | 810K | 1.02M | 1.02M |
| Retained Earnings | -93.59M | -126.3M | -168.17M | -278.89M | -358.3M | -488.17M | -725.91M | -995.86M | -1.34B | -1.44B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.83M | -3K | 0 | -8K | -157K | -390K | 338K | -10K | 447K | -558K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VRDN Cash Flow Statement
Viridian Therapeutics, Inc. (VRDN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -28.17M | -26.84M | -36.06M | -29.78M | -54.58M | -93.84M | -184.17M | -232.32M | -276.39M | -276.39M |
| Operating CF Margin % | -703.65% | -320.1% | -808.25% | -2836.1% | -1842.09% | -5295.6% | -58652.87% | -76926.82% | -390.11% | - |
| Operating CF Growth % | -289.53% | 4.7% | -34.32% | 17.41% | -83.29% | -71.92% | -96.26% | -26.14% | -18.97% | -50.15% |
| Net Income | -26.51M | -32.7M | -41.87M | -110.72M | -79.41M | -129.87M | -237.73M | -269.95M | -342.6M | -360.59M |
| Depreciation & Amortization | 308K | 281K | 288K | 239K | 120K | 255K | 522K | 540K | -6.76M | -524K |
| Stock-Based Compensation | 2.41M | 3.68M | 3.97M | 3.65M | 14.46M | 19.77M | 67.17M | 42.15M | 44.3M | 47.47M |
| Deferred Taxes | 0 | -416K | -432K | 56K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 94K | 376K | 340K | 72.57M | 8.52M | 54K | -4.71M | -14.66M | 5.63M | -5.25M |
| Working Capital Changes | -4.47M | 1.94M | 1.65M | 4.43M | 1.72M | 15.96M | -9.43M | 9.6M | 23.03M | 15.5M |
| Change in Receivables | -1.44M | 1.43M | -84K | 99K | -451K | 349K | 0 | 102K | 0 | -70M |
| Change in Inventory | -50.9M | -57.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -101K | -335K | 525K | -426K | 1.66M | 11.52M | -12.04M | -73K | 6.56M | 9.43M |
| Cash from Investing | 1.03M | -29.91M | 28.23M | -50.48M | -74.29M | -115.13M | -94.25M | -228.65M | -37.56M | -60.36M |
| Capital Expenditures | -246K | -445K | -84K | -42K | -338K | -797K | -898K | -511K | -495K | -432K |
| CapEx % of Revenue | 6.15% | 5.31% | 1.88% | 4% | 11.41% | 44.98% | 285.99% | 169.21% | 0.7% | - |
| Acquisitions | 1.28M | 0 | -28.31M | 29.37M | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.28M | -29.46M | 28.31M | -3K | 79K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 52.47M | 41.92M | 70K | 101.31M | 125.28M | 322.24M | 225.67M | 457.74M | 426.74M | 423.89M |
| Debt Issued (Net) | 5.33M | 0 | -2.33M | -8.57M | 0 | 5M | 15M | 0 | 28.88M | 28.88M |
| Equity Issued (Net) | 48.56M | 44.53M | 2.4M | 116.1M | 131.2M | 335.87M | 201.26M | 478.66M | 348.33M | 343.81M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.43M | -2.61M | 0 | -6.22M | -5.93M | -18.63M | 9.41M | -20.92M | 49.54M | 51.2M |
| Net Change in Cash | 25.34M▲ 0% | -14.84M▼ 158.6% | -7.76M▲ 47.7% | 21.05M▲ 371.3% | -3.6M▼ 117.1% | 113.28M▲ 3248.4% | -52.75M▼ 146.6% | -3.23M▲ 93.9% | 112.79M▲ 3588.6% | 60.13M▲ 0% |
| Free Cash Flow | -28.41M▲ 0% | -27.29M▲ 4.0% | -36.14M▼ 32.4% | -29.82M▲ 17.5% | -54.92M▼ 84.2% | -94.64M▼ 72.3% | -185.07M▼ 95.6% | -232.83M▼ 25.8% | -276.89M▼ 18.9% | -303.82M▲ 0% |
| FCF Margin % | -709.79% | -325.41% | -810.13% | -2840.1% | -1853.49% | -5340.58% | -58938.85% | -77096.03% | -390.81% | -428.42% |
| FCF Growth % | -292.77% | 3.96% | -32.43% | 17.48% | -84.16% | -72.32% | -95.56% | -25.81% | -18.92% | -8.37% |
| FCF per Share | -22.15 | -13.83 | -17.30 | -8.38 | -4.61 | -2.95 | -4.14 | -3.43 | -3.27 | -3.27 |
| FCF Conversion (FCF/Net Income) | 1.06x | 0.82x | 0.86x | 0.27x | 0.69x | 0.72x | 0.77x | 0.86x | 0.81x | 0.84x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 293K | 0 | 1.82M | 0 | 914K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VRDN Key Ratios
Viridian Therapeutics, Inc. (VRDN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -138.86% | -72.79% | -124.81% | -163.07% | -51.61% | -44.57% | -56.8% | -48.48% | -49.16% | -60.7% |
| Return on Invested Capital (ROIC) | -2007.97% | -165.27% | -222.91% | -224.33% | -54.23% | -51.57% | -63.09% | -47.05% | -47.25% | -47.25% |
| Gross Margin | -390.21% | -262.76% | 100% | -2595.62% | 100% | 100% | 100% | 100% | 100% | 99.38% |
| Net Margin | -662.3% | -389.97% | -938.65% | -10544.29% | -2680.16% | -7329.23% | -75711.46% | -89387.09% | -483.56% | -508.46% |
| Debt / Equity | 0.26x | 0.20x | 0.53x | 0.00x | 0.00x | 0.01x | 0.05x | 0.03x | 0.07x | 0.07x |
| Interest Coverage | -68.22x | -36.46x | -49.15x | -79.76x | -26470.00x | -266.23x | -127.71x | -87.62x | -68.24x | -32.68x |
| FCF Conversion | 1.06x | 0.82x | 0.86x | 0.27x | 0.69x | 0.72x | 0.77x | 0.86x | 0.81x | 0.84x |
| Revenue Growth | 19.96% | 109.49% | -46.8% | -76.46% | 182.19% | -40.2% | -82.28% | -3.82% | 23359.93% | 23382.78% |
VRDN SEC Filings & Documents
Viridian Therapeutics, Inc. (VRDN) SEC filings — annual & quarterly reports (10-K, 10-Q)
VRDN Frequently Asked Questions
Viridian Therapeutics, Inc. (VRDN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Viridian Therapeutics, Inc. (VRDN) reported $70.9M in revenue for fiscal year 2025. This represents a 1510% increase from $4.4M in 2012.
Viridian Therapeutics, Inc. (VRDN) grew revenue by 23359.9% over the past year. This is strong growth.
Viridian Therapeutics, Inc. (VRDN) reported a net loss of $360.6M for fiscal year 2025.
Dividend & Returns
Viridian Therapeutics, Inc. (VRDN) has a return on equity (ROE) of -49.2%. Negative ROE indicates the company is unprofitable.
Viridian Therapeutics, Inc. (VRDN) had negative free cash flow of $303.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More VRDN
Viridian Therapeutics, Inc. (VRDN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates